The Inspiration Blog

The IRL team is committed to ongoing research and education. We hope you enjoy reading about current trial publications. Please feel free to contact with any of your questions or comments.

1703, 2016

DECAF score predicts acute COPD exacerbation mortality

DECAF score predicts acute COPD exacerbation mortality Preventing COPD exacerbations has become an important goal in clinical management and a primary outcome in many COPD research trials. This is understandable - not only is the worsening of COPD distressing for patients but exacerbations can be severe enough to result in hospitalization and death. Unfortunately, as the health care dollar is stretched, more and more institutions are keeping hospital stays short or avoiding hospital stays altogther by using home care. This is safe only if we can identify low-risk patients or, put in reverse terms, identify the high risk [...]

1603, 2016

COPD Symposium Online!

COPD Symposium Online! I’ve been slow to catch up to this development even though I’ve been a part of it. Each year, the European Respiratory Society holds its annual scientific meeting to share late-breaking news in the field of respiratory medicine. It’s a sprawling meeting hosting more than 20,000 international attendees who may attend sessions on developments in common lung conditions or blue-sky speculative science discussions on rare diseases. It’s easy to miss something of interest. Many of the posters and abstracts can be tracked down online after the meeting is over but this option is open only [...]

1405, 2014

Inspiration Research Contributes to Groundbreaking Study

Inspiration Research Contributes to Groundbreaking Study KAMADA Pharmaceutical ("Kamada") conducted a Phase II/III clinical trial on the efficacy of proprietary inhaled Alpha-­1 Antitrypsin (AAT) therapy for the treatment of Alpha-­1 Antitrypsin Deficiency (AATD or inherited emphysema) which involved a multi-centre, randomized, double-blind, placebo-controlled study designed to evaluate Kamada's formulation of human AAT to treat AATD in 168 patients. Inspiration Research Ltd. ("IRL") was one of the centres involved in this trial. IRL's contribution to this study resulted in groundbreaking preliminary finding that "[participants in the] inhaled AAT group including an approximate 50% reduction in severe exacerbation rates versus [...]


Do not hesitate to contact us for any questions relating to our pulmonary function tests or clinical trials